Treatment of al amyloidosis with melphalan, prednisone, and colchicine

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

Seven patients with immunoglobulin type (AL) amyloidosis were treated with combination chemotherapy, including melphalan, prednisone, and colchicine. Two patients died within 5 months of the beginning of therapy. Both had amyloid cardiomyopathy. Five patients were alive 17-60 months after the start of therapy, and none had shown progression of disease. The most significant findings were the resolution of the nephrotic syndrome in 2 patients, and improvement of liver function, as demonstrated by excretion of indocyanine green, in 2 patients. These results are encouraging and support the need for further studies of this regimen of combination chemotherapy for patients with AL amyloidosis.

Original languageEnglish (US)
Pages (from-to)683-687
Number of pages5
JournalArthritis & Rheumatism
Volume29
Issue number5
DOIs
StatePublished - May 1986

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Treatment of al amyloidosis with melphalan, prednisone, and colchicine'. Together they form a unique fingerprint.

  • Cite this